private:relmadatherapeutics
|
2601251
|
May 31st, 2019 12:00AM
|
Relmada Therapeutics, Inc
|
370
|
9.00
|
Open
|
Pharmaceuticals
|
May 31st, 2019 10:38AM
|
May 31st, 2019 10:38AM
|
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain.
Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com
|
Open
|
Analgesic Drug Development, Chronic Pain, Pharmaceutical Development, Opioid Addiction
|
Open
|
757 Third Ave, 20th Floor
|
New York
|
NY
|
US
|
10017
|
|
Relmada Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:relmadatherapeutics
|
2601251
|
Feb 17th, 2018 12:00AM
|
Relmada Therapeutics, Inc
|
275
|
8.00
|
Open
|
Pharmaceuticals
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain.
Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com
|
|
|
|
|
|
|
|
|
|
Relmada Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:relmadatherapeutics
|
2601251
|
Feb 16th, 2018 12:00AM
|
Relmada Therapeutics, Inc
|
275
|
8.00
|
Open
|
Pharmaceuticals
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain.
Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com
|
|
|
|
|
|
|
|
|
|
Relmada Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:relmadatherapeutics
|
2601251
|
Feb 15th, 2018 12:00AM
|
Relmada Therapeutics, Inc
|
275
|
8.00
|
Open
|
Pharmaceuticals
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain.
Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com
|
|
|
|
|
|
|
|
|
|
Relmada Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:relmadatherapeutics
|
2601251
|
Feb 14th, 2018 12:00AM
|
Relmada Therapeutics, Inc
|
275
|
8.00
|
Open
|
Pharmaceuticals
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain.
Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com
|
|
|
|
|
|
|
|
|
|
Relmada Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:relmadatherapeutics
|
2601251
|
Feb 13th, 2018 12:00AM
|
Relmada Therapeutics, Inc
|
275
|
8.00
|
Open
|
Pharmaceuticals
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain.
Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com
|
|
|
|
|
|
|
|
|
|
Relmada Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:relmadatherapeutics
|
2601251
|
Feb 12th, 2018 12:00AM
|
Relmada Therapeutics, Inc
|
275
|
8.00
|
Open
|
Pharmaceuticals
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain.
Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com
|
|
|
|
|
|
|
|
|
|
Relmada Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:relmadatherapeutics
|
2601251
|
Feb 11th, 2018 12:00AM
|
Relmada Therapeutics, Inc
|
275
|
8.00
|
Open
|
Pharmaceuticals
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain.
Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com
|
|
|
|
|
|
|
|
|
|
Relmada Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:relmadatherapeutics
|
2601251
|
Feb 10th, 2018 12:00AM
|
Relmada Therapeutics, Inc
|
275
|
8.00
|
Open
|
Pharmaceuticals
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain.
Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com
|
|
|
|
|
|
|
|
|
|
Relmada Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:relmadatherapeutics
|
2601251
|
Feb 9th, 2018 12:00AM
|
Relmada Therapeutics, Inc
|
275
|
8.00
|
Open
|
Pharmaceuticals
|
Feb 9th, 2017 08:57AM
|
Feb 9th, 2017 08:57AM
|
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain.
Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com
|
|
|
|
|
|
|
|
|
|
Relmada Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|